Platelet Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention: Glycoprotein IIb/IIIa Inhibitors, Clopidogrel, or Both?

References

• BatchelorWBTollesonTRHuangYRandomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and EptifibatideCirculation20021061470612234950
   PubMed Web of Science ®Google Scholar
• BhattDLScientific and therapeutic advances in antiplatelet therapyNat Rev Drug Discov20032152812509756
   PubMed Web of Science ®Google Scholar
• BraunwaldEAntmanEMBeasleyJWACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – 2002: summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the management of patients with unstable angina)Circulation20021061893190012356647
   PubMed Web of Science ®Google Scholar
• CannonCPWhat is the optimal timing of clopidogrel in acute coronary syndromes?Crit Pathways in Cardiol200544650
   PubMedGoogle Scholar
• [CAPTURE] CAPTURE InvestigatorsRandomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyLancet19973491429359164316
   PubMed Web of Science ®Google Scholar
• Cook-MillsJVCAM-1 signals during lymphocyte migration: role of reactive oxygen speciesMol Immunol20023949950812431382
   PubMed Web of Science ®Google Scholar
• DalbyMMontalescotGBal dit SollierCEptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: Results of the platelet activity extinction in non-Q-Wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) studyJ Am Coll Cardiol200443162814736431
   PubMed Web of Science ®Google Scholar
• EgashiraKMolecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1Hypertension2003418344112624005
   PubMed Web of Science ®Google Scholar
• [EPIC] The EPIC InvestigatorsUse of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in highrisk coronary angioplasty. The EPIC InvestigationN Engl J Med1994330956618121459
   PubMed Web of Science ®Google Scholar
• [EPILOG] EPILOG InvestigatorsPlatelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularizationN Engl J Med19973361689969182212
   PubMed Web of Science ®Google Scholar
• [ESPRIT] ESPRIT Investigators; Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin TherapyNovel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialLancet200035620374411145489
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPZamanKAClopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR-PLATELETS) studyCirculation20051111153915738352
   PubMed Web of Science ®Google Scholar
• GurbelPAGalbutBBlidenKPEffect of eptifibatide for acute coronary syndromes: rapid versus late administration—therapeutic yield on platelets (The EARLY Platelet Substudy)J Thromb Thrombolysis2002142131912913401
   PubMed Web of Science ®Google Scholar
• HoekstraJWRoeMTPetersonEDEarly glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patternsAcad Emerg Med200512431815863399
   PubMed Web of Science ®Google Scholar
• IiyamaKHajraLIiyamaMPatterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formationCirc Res19998519920710417402
   PubMed Web of Science ®Google Scholar
• [IMPACT-II] IMPACT-II InvestigatorsRandomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-IILancet19973491422889164315
   PubMed Web of Science ®Google Scholar
• JiangYBellerDIFrendlGMonocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytesJ Immunol1992148242381348518
   PubMed Web of Science ®Google Scholar
• KandzariDEBergerPBKastratiAISAR-REACT Study InvestigatorsInfluence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularizationJ Am Coll Cardiol2004442133615582309
   PubMed Web of Science ®Google Scholar
• LauWCGurbelPAWatkinsPBContribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistanceCirculation20041091667114707025
   PubMed Web of Science ®Google Scholar
• MahoneyEMJurkovitzCTChuHTACTICS-TIMI 18 Investigators. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial InfarctionCost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarctionJAMA20022881851812377083
   PubMed Web of Science ®Google Scholar
• Maksimowicz-McKinnonKBhattDLCalabreseLHRecent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkersCurr Opin Rheumatol200416182414673384
   PubMedGoogle Scholar
• MehilliJKastratiASchühlenHIntracoronary Stenting and Antithrombotic Regimen – Rapid Early Action for Coronary Treatment (ISAR-REACT) Study InvestigatorsRandomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrelCirculation200411036273515531766
   PubMed Web of Science ®Google Scholar
• MehtaSRYusufSPetersRJClopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) InvestigatorsEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyLancet20013585273311520521
   PubMed Web of Science ®Google Scholar
• MüllerIBestaFSchulzCPrevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placementThromb Haemost200389783712719773
   PubMed Web of Science ®Google Scholar
• O'SheaJCBullerCECantorWJESPRIT InvestigatorsLongterm efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent interventionJAMA20022876182111829701
   PubMed Web of Science ®Google Scholar
• PattiGColonnaGPasceriVRandomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) studyCirculation2005111209910615750189
   PubMed Web of Science ®Google Scholar
• PetersonEDPollackJCharlesVNational Registry of Myocardial Infarction (NRMI) 4 InvestigatorsEarly use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4J Am Coll Cardiol200342455312849658
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNPfefferMElevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarctionCirculation200010121495310801754
   PubMed Web of Science ®Google Scholar
• RoffiMChewDPMukherjeeDPlatelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-STsegment-elevation acute coronary syndromesCirculation200110427677111733392
   PubMed Web of Science ®Google Scholar
• SackMTumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart diseasePharmacol Ther2002941233512191598
   PubMed Web of Science ®Google Scholar
• SaucedoJFAudeWPachecoRInhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study)Am J Cardiol2005951453615950569
   PubMed Web of Science ®Google Scholar
• SilvaMGandhiPJSelection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?J Clin Pharm Ther20042949751015584937
   PubMed Web of Science ®Google Scholar
• SimoonsMLGUSTO IV-ACS InvestigatorsEffect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialLancet200135719152411425411
   PubMed Web of Science ®Google Scholar
• SmithJSidneyCDoveJTACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) – executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and InterventionsJ Am Coll Cardiol20013722153811419905
   PubMed Web of Science ®Google Scholar
• SonelAFGoodCBMulgundJCRUSADE InvestigatorsRacial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?)Circulation200511112253215769762
   PubMed Web of Science ®Google Scholar
• SteinhublSREllisSGWolskiKTiclopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) TrialCirculation20011031403911245644
   PubMed Web of Science ®Google Scholar
• [PRISM] Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study InvestigatorsA comparison of aspirin plus tirofiban with aspirin plus heparin for unstable anginaN Engl J Med1998338149815059599104
   PubMed Web of Science ®Google Scholar
• [PRISM-PLUS] Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study InvestigatorsInhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarctionN Engl J Med19983381488979599103
   PubMed Web of Science ®Google Scholar
• [PURSUIT] PURSUIT Trial InvestigatorsInhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromesN Engl J Med1998339436439705684
   PubMed Web of Science ®Google Scholar
• [RESTORE] RESTORE InvestigatorsEffects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplastyCirculation1997961445539315530
   PubMedGoogle Scholar
• TopolEJLincoffAMKereiakesDJMulti-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularizationAm J Med20021131612106616
   PubMed Web of Science ®Google Scholar
• ViedtCVogelJAthanasiouTMonocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1Arterioscler Thromb Vasc Biol2002229142012067898
   PubMed Web of Science ®Google Scholar
• YamamotoTEckesBMauchCMonocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loopJ Immunol20001646174910843667
   PubMed Web of Science ®Google Scholar
• YusufSMehtaSRZhaoFClopidogrel in Unstable angina to prevent Recurrent Events Trial InvestigatorsEarly and late effects of clopidogrel in patients with acute coronary syndromesCirculation20031079667212600908
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSRClopidogrel in Unstable Angina to Prevent Recurrent Events Trial InvestigatorsEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med200134549450211519503
   PubMed Web of Science ®Google Scholar